Literature DB >> 17898800

Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.

E D Grober1, M Khera, S D Soni, M G Espinoza, L I Lipshultz.   

Abstract

The study objective was to evaluate the efficacy of changing testosterone gel preparations among suboptimally responsive hypogonadal men. The records of all hypogonadal men on gel (Testim or Androgel) testosterone replacement therapy (TRT) were reviewed to identify men who underwent a brand substitution in gel TRT due to initial suboptimal response. Total and free serum testosterone levels and the presence of hypogonadal symptoms (ADAM) were compared pre- and post-gel substitution. Of the 370 hypogonadal men on testosterone gel replacement therapy, 75 (20%) underwent a brand substitution. Prior to substitution, among patients initially treated with Androgel, the mean total and free testosterone levels were 311 ng dl(-1) and 10.4 pg ml(-1), respectively. Total testosterone levels were below 300 ng dl(-1) in 58% of these patients. Following a change to Testim, mean total and free testosterone levels increased to 484 ng dl(-1) (P<0.001) and 14.6 pg ml(-1) (P=0.01), respectively. Total testosterone levels remained below 300 ng dl(-1) in only 17% of these patients. Among patients initially treated with Testim, the mean total and free testosterone levels were 544 ng dl(-1) and 18.0 pg ml(-1), respectively. Total testosterone levels were below 300 ng dl(-1) in 15% of men. Following testosterone gel change to Androgel, mean total and free testosterone levels were 522 ng dl(-1) (P=0.7) and 16.1 pg ml(-1) (P=0.6), respectively. Total testosterone levels remained below 300 ng dl(-1) in 27% of these patients. Hypogonadal symptoms improved in a significant proportion of men who underwent a brand substitution following an initial suboptimal biochemical or symptomatic response. A change in testosterone gel preparation among initially unresponsive hypogonadal men is justified prior to abandoning or considering more invasive TRT. Changing from Androgel to Testim offers hypogonadal men the potential for improved clinical and biochemical responsiveness. Changing from Testim to Androgel is indicated to eliminate or minimize unwanted side effects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17898800     DOI: 10.1038/sj.ijir.3901618

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  6 in total

1.  The Effect of Testosterone Topical Solution in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel.

Authors:  Patrick R Burns; Edward D Kim; Dustin D Ruff; Allen D Seftel
Journal:  Am J Mens Health       Date:  2015-10-05

2.  Oxidative stress, testosterone, and cognition among Caucasian and Mexican-American men with and without Alzheimer's disease.

Authors:  Rebecca L Cunningham; Meharvan Singh; Sid E O'Bryant; James R Hall; Robert C Barber
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

3.  Patient satisfaction with testosterone replacement therapies: the reasons behind the choices.

Authors:  Jason R Kovac; Saneal Rajanahally; Ryan P Smith; Robert M Coward; Dolores J Lamb; Larry I Lipshultz
Journal:  J Sex Med       Date:  2013-11-06       Impact factor: 3.802

Review 4.  Safety and efficacy of testosterone gel in the treatment of male hypogonadism.

Authors:  Kishore M Lakshman; Shehzad Basaria
Journal:  Clin Interv Aging       Date:  2009-11-18       Impact factor: 4.458

Review 5.  Transdermal testosterone replacement therapy in men.

Authors:  M Iftekhar Ullah; Daniel M Riche; Christian A Koch
Journal:  Drug Des Devel Ther       Date:  2014-01-09       Impact factor: 4.162

Review 6.  Diagnosis and management of testosterone deficiency.

Authors:  James A McBride; Culley C Carson; Robert M Coward
Journal:  Asian J Androl       Date:  2015 Mar-Apr       Impact factor: 3.285

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.